# Pharmacokinetic Interactions of ENG Subdermal Implants with Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA)

> **NCT05156658** · PHASE4 · WITHDRAWN · sponsor: **Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections**

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Etonogestrel (ENG) Subdermal Implants

## Key facts

- **NCT ID:** NCT05156658
- **Lead sponsor:** Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-01-01
- **Primary completion:** 2024-08-02
- **Final completion:** 2024-08-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Protocol's question was answered elsewhere and very low site interest in the trial
- **Last updated:** 2024-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05156658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05156658, "Pharmacokinetic Interactions of ENG Subdermal Implants with Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05156658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*